[Thrombocytopathies and their role in the development of hemorrhagic syndrome in vascular diseases of the fundus oculi].
Examinations of 407 patients with angiological disorders of the fundus oculi (diabetic retinopathy, retinal vein thrombosis, central chorioretinal dystrophy, retinal angiitis) revealed relapsing hemorrhagic syndrome in 40% (170) patients. No thrombocytopenia was revealed in any of the patients, which suggests qualitative impairment of platelets in such patients. Evaluation of the platelet aggregation coefficient (PAC) using thrombin aggregation inducers and adenosine diphosphate disodium revealed a statistically significant decrease of PAC for one or both aggregants in all 170 patients with the hemorrhagic syndrome, which indicated platelet dysfunction. A course of intramuscular injections of 1% adenosine triphosphate sodium normalized platelet function and stimulated resorption of hemorrhages.
Lysenko
V S
VS
Mukha
A I
AI
Bunin
A Ia
AIa
Fedorova
N V
NV
D000255:Adenosine Triphosphate / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001780:Blood Coagulation Tests; D001791:Blood Platelet Disorders / Q000150:complications* / Q000175:diagnosis; D002825:Chorioretinitis / Q000150:complications; D003930:Diabetic Retinopathy / Q000150:complications; D005123:Eye / Q000098:blood supply*; D005260:Female; D005654:Fundus Oculi; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D012164:Retinal Diseases / Q000150:complications*; D012170:Retinal Vein Occlusion / Q000150:complications; D013577:Syndrome; D014657:Vasculitis / Q000150:complications
D000255:Adenosine Triphosphate